secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2023-12-05T23:59:59+00:00
Accession:  0001516551-23-000103
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 1.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye licenses SBI-100 to Tautomer for Africa, terminates UM 8930 license, sells Canadian lab
--------------------------------------------------------------------------------

- Exclusive license to Tautomer for SBI-100 (THC prodrug) suppository in Africa for chronic pain and other indications.
- Tautomer to buy $500K of Skye stock within 60 days; potential milestones up to $10.75M plus double-digit royalties.
- Terminated UM 8930 license (SBI-200) effective Jan 30, 2024; no milestones met beyond initial $200K payment.
- Sold Avalite lab facility in Canada for CAD $1.499M; closing expected Jan 15, 2024.
- Skye retains exclusive, perpetual license for UM 5050; deal subject to South African exchange control approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000151655123000103/0001516551-23-000103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000151655123000103/skye-20231129.htm
  HTML page:      https://secwatch.observer/filing/0001516551-23-000103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer